UK markets close in 8 hours 11 minutes

Protagonist Therapeutics, Inc. (PTGX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
28.23-0.04 (-0.14%)
At close: 04:00PM EDT
28.23 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.66B
Enterprise value 1.33B
Trailing P/E 11.11
Forward P/E 21.69
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.38
Price/book (mrq)2.95
Enterprise value/revenue 1.00k
Enterprise value/EBITDA -7.20

Trading information

Stock price history

Beta (5Y monthly) 2.08
52-week change 38.70%
S&P500 52-week change 326.27%
52-week high 333.34
52-week low 313.72
50-day moving average 327.84
200-day moving average 322.12

Share statistics

Avg vol (3-month) 3554.31k
Avg vol (10-day) 3526.83k
Shares outstanding 558.65M
Implied shares outstanding 658.65M
Float 841.03M
% held by insiders 11.24%
% held by institutions 1102.92%
Shares short (30 Apr 2024) 43.73M
Short ratio (30 Apr 2024) 46.86
Short % of float (30 Apr 2024) 46.46%
Short % of shares outstanding (30 Apr 2024) 46.37%
Shares short (prior month 28 Mar 2024) 43.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 51.47%
Operating margin (ttm)80.92%

Management effectiveness

Return on assets (ttm)21.38%
Return on equity (ttm)41.75%

Income statement

Revenue (ttm)314.95M
Revenue per share (ttm)5.31
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA 149.64M
Net income avi to common (ttm)162.11M
Diluted EPS (ttm)2.54
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)322.64M
Total cash per share (mrq)5.5
Total debt (mrq)462k
Total debt/equity (mrq)0.08%
Current ratio (mrq)15.72
Book value per share (mrq)9.56

Cash flow statement

Operating cash flow (ttm)-63.32M
Levered free cash flow (ttm)-154.68M